TY - JOUR
T1 - Chinese herbal medicine (Mazirenwan) improves bowel movement in functional constipation through down-regulating oleamide
AU - Huang, Tao
AU - Zhao, Ling
AU - Lin, Cheng Yuan
AU - Lu, Lin
AU - Ning, Zi Wan
AU - Hu, Dong Dong
AU - Zhong, Lidan
AU - Yang, Zhijun
AU - Bian, Zhaoxiang
N1 - Funding Information:
This study was supported by the Health and Health Services Fund, Hong Kong SAR, P. R. China (project no. 09101501) and Shenzhen Science and Technology Innovations Committee (No. JCYJ20140419130444178). The sponsors have no roles in study design, collection, analysis, and interpretation of the data and in the writing of the manuscript.
Funding Information:
This study was supported by the Health and Health Services Fund, Hong Kong SAR, P. R. China (project no. 09101501) and Shenzhen Science and Technology Innovations Committee (No. JCYJ20140419130444178). The sponsors have no roles in study design, collection, analysis, and interpretation of the data and in the writing of the manuscript. The authors thank all the members of MZRW research group, including Prof. Shu-Hai Lin, Dr. Man Zhang, Dr. Yan-Hong Li, and Miss Chung-Wah Cheng, for their great support and fruitful discussions. Part of this study has been included in Tao Huang's PhD Thesis (Huang, 2017).
PY - 2020/1/23
Y1 - 2020/1/23
N2 - In a prospective, randomized, three-arms, controlled clinical study, Chinese Herbal Medicine MaZiRenWan (MZRW, also known as Hemp Seed Pill) demonstrates comparable efficacy with Senna for functional constipation (FC) during an 8-week treatment period. Both MZRW and Senna are better than a placebo; relative to Senna and a placebo, MZRW displayed a more sustained effect during the 8-week follow-up period. The characteristic pharmacological mechanism responsible for this observation is still unclear. To explore this, we collected pre- and post-treatment serum samples of 85 FC patients from MZRW/Senna/placebo treatment groups for pharmacometabolomic analysis. An ultrahigh-performance liquid chromatography-mass spectrometer (UPLC-MS) was used for metabolic profiling and quantification. In vivo studies were conducted in constipated C57BL/6J mice to verify the effects and corresponding mechanism(s) of the action of MZRW. Pearson correlation analysis, paired t-test, one-way ANOVA analysis, c2 test, and Student t-test were used to interpret the clinical and preclinical data. Changes in levels of circulating oleamide and its derivatives negatively correlate with improvement in complete spontaneous bowel movement (CSBM) in the MZRW group (Pearson r = -0.59, p = 0.00057). The same did not hold true for either Senna or placebo groups. Oleamide is a known regulator of intestinal motility. MZRW treatment resulted in reduced levels of circulating oleamide in FC patients. Experimental verification showed that MZRW attenuated oleamide-induced slow intestinal motility in mice. MZRW decreased oleamide levels in serum, ileum, and colon in normal mice, but increased expression of colonic fatty acid amide hydrolase (FAAH). In conclusion, MZRW improved bowel movement in FC by down-regulating oleamide, possibly by enhancing FAAH-mediated degradation. Our findings suggest a novel therapeutic strategy for FC.
AB - In a prospective, randomized, three-arms, controlled clinical study, Chinese Herbal Medicine MaZiRenWan (MZRW, also known as Hemp Seed Pill) demonstrates comparable efficacy with Senna for functional constipation (FC) during an 8-week treatment period. Both MZRW and Senna are better than a placebo; relative to Senna and a placebo, MZRW displayed a more sustained effect during the 8-week follow-up period. The characteristic pharmacological mechanism responsible for this observation is still unclear. To explore this, we collected pre- and post-treatment serum samples of 85 FC patients from MZRW/Senna/placebo treatment groups for pharmacometabolomic analysis. An ultrahigh-performance liquid chromatography-mass spectrometer (UPLC-MS) was used for metabolic profiling and quantification. In vivo studies were conducted in constipated C57BL/6J mice to verify the effects and corresponding mechanism(s) of the action of MZRW. Pearson correlation analysis, paired t-test, one-way ANOVA analysis, c2 test, and Student t-test were used to interpret the clinical and preclinical data. Changes in levels of circulating oleamide and its derivatives negatively correlate with improvement in complete spontaneous bowel movement (CSBM) in the MZRW group (Pearson r = -0.59, p = 0.00057). The same did not hold true for either Senna or placebo groups. Oleamide is a known regulator of intestinal motility. MZRW treatment resulted in reduced levels of circulating oleamide in FC patients. Experimental verification showed that MZRW attenuated oleamide-induced slow intestinal motility in mice. MZRW decreased oleamide levels in serum, ileum, and colon in normal mice, but increased expression of colonic fatty acid amide hydrolase (FAAH). In conclusion, MZRW improved bowel movement in FC by down-regulating oleamide, possibly by enhancing FAAH-mediated degradation. Our findings suggest a novel therapeutic strategy for FC.
KW - Fatty acid amide hydrolase
KW - Functional constipation
KW - MaZiRenWan
KW - Oleamide
KW - Pharmacometabolomics
UR - http://www.scopus.com/inward/record.url?scp=85079123074&partnerID=8YFLogxK
U2 - 10.3389/fphar.2019.01570
DO - 10.3389/fphar.2019.01570
M3 - Journal article
AN - SCOPUS:85079123074
SN - 1663-9812
VL - 10
JO - Frontiers in Pharmacology
JF - Frontiers in Pharmacology
M1 - 1570
ER -